NO329149B1 - Syntetiske peptider, blandinger, immunoassaymetode og diagnostiseringssett - Google Patents

Syntetiske peptider, blandinger, immunoassaymetode og diagnostiseringssett Download PDF

Info

Publication number: NO329149B1
Authority: NO; Norway
Prior art keywords: peptides; peptide; radical; seq; group
Prior art date: 1997-04-09

Application number

NO19994929A

Other languages

English (en)

Norwegian (no)

Other versions

NO994929D0 (no

NO994929L (no

Inventor

Denis Marie Bernard Chenebaux

Jean-Francois Hubert Delagneau

St Phane Jean Xavier Gadelle

Francois Yves Unier

Original Assignee

Bio Rad Pasteur

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-09

Filing date

1999-10-08

Publication date

2010-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26233456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO329149(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-04-09 Priority claimed from FR9704356A external-priority patent/FR2761993B1/fr

1998-02-24 Priority claimed from FR9802212A external-priority patent/FR2775287B1/fr

1999-10-08 Application filed by Bio Rad Pasteur filed Critical Bio Rad Pasteur

1999-10-08 Publication of NO994929D0 publication Critical patent/NO994929D0/no

1999-12-08 Publication of NO994929L publication Critical patent/NO994929L/no

2010-08-30 Publication of NO329149B1 publication Critical patent/NO329149B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 131
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 76
239000000203 mixture Substances 0.000 title claims description 21
238000003018 immunoassay Methods 0.000 title claims description 6
238000009007 Diagnostic Kit Methods 0.000 title claims description 4
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 31
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
208000031886 HIV Infections Diseases 0.000 claims description 3
241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 3
150000001413 amino acids Chemical class 0.000 abstract description 20
125000003277 amino group Chemical group 0.000 abstract description 2
-1 is OH Chemical compound 0.000 abstract description 2
125000004432 carbon atom Chemical group C* 0.000 abstract 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
239000004472 Lysine Substances 0.000 abstract 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
125000001931 aliphatic group Chemical group 0.000 abstract 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
239000000178 monomer Substances 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
150000003573 thiols Chemical class 0.000 abstract 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
239000004474 valine Substances 0.000 abstract 1
239000000243 solution Substances 0.000 description 18
241001430294 unidentified retrovirus Species 0.000 description 17
239000011347 resin Substances 0.000 description 16
229920005989 resin Polymers 0.000 description 16
238000012360 testing method Methods 0.000 description 14
230000015572 biosynthetic process Effects 0.000 description 13
238000003786 synthesis reaction Methods 0.000 description 13
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
101800001690 Transmembrane protein gp41 Proteins 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
239000007853 buffer solution Substances 0.000 description 8
238000000034 method Methods 0.000 description 8
239000000427 antigen Substances 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
238000002835 absorbance Methods 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
239000007790 solid phase Substances 0.000 description 6
238000001514 detection method Methods 0.000 description 5
229920000136 polysorbate Polymers 0.000 description 5
238000004366 reverse phase liquid chromatography Methods 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 4
239000007979 citrate buffer Substances 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
230000000405 serological effect Effects 0.000 description 4
238000005406 washing Methods 0.000 description 4
DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 3
241000700605 Viruses Species 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
235000020183 skimmed milk Nutrition 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 3
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
206010070834 Sensitisation Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000001351 cycling effect Effects 0.000 description 2
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
239000012071 phase Substances 0.000 description 2
229960003531 phenolsulfonphthalein Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000008313 sensitization Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
101150048348 GP41 gene Proteins 0.000 description 1
241000560056 HIV-1 group O Species 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
108700004025 env Genes Proteins 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
108700004026 gag Genes Proteins 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000006166 lysate Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
239000002994 raw material Substances 0.000 description 1
239000000523 sample Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
AIDS & HIV (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO19994929A 1997-04-09 1999-10-08 Syntetiske peptider, blandinger, immunoassaymetode og diagnostiseringssett NO329149B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR9704356A FR2761993B1 (fr)	1997-04-09	1997-04-09	Peptides synthetiques utilisables dans les essais biologiques pour la detection des infections dues aux virus vih 1 groupe 0
FR9802212A FR2775287B1 (fr)	1998-02-24	1998-02-24	Peptides synthetiques consensus utilisables dans les essais biologiques pour la detection des infections dues aux virus vih 1 du groupe o
PCT/FR1998/000691 WO1998045323A1 (fr)	1997-04-09	1998-04-06	Peptides synthetiques utilisables dans les essais biologiques pour la detection des infections dues aux virus vih-1 du groupe o

Publications (3)

Publication Number	Publication Date
NO994929D0 NO994929D0 (no)	1999-10-08
NO994929L NO994929L (no)	1999-12-08
NO329149B1 true NO329149B1 (no)	2010-08-30

Family

ID=26233456

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19994929A NO329149B1 (no)	1997-04-09	1999-10-08	Syntetiske peptider, blandinger, immunoassaymetode og diagnostiseringssett

Country Status (20)

Country	Link
US (2)	US7053175B1 (pl)
EP (1)	EP0973802B1 (pl)
JP (1)	JP3560987B2 (pl)
KR (1)	KR100451312B1 (pl)
CN (1)	CN1215082C (pl)
AT (1)	ATE343590T1 (pl)
AU (1)	AU740231B2 (pl)
BR (1)	BRPI9809078B8 (pl)
CA (1)	CA2286344C (pl)
CZ (1)	CZ300927B6 (pl)
DE (1)	DE69836265T2 (pl)
ES (1)	ES2275305T3 (pl)
IL (2)	IL132166A0 (pl)
NO (1)	NO329149B1 (pl)
NZ (1)	NZ500015A (pl)
PL (1)	PL194863B1 (pl)
PT (1)	PT973802E (pl)
RU (1)	RU2184742C2 (pl)
TR (1)	TR199902757T2 (pl)
WO (1)	WO1998045323A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ300927B6 (cs) *	1997-04-09	2009-09-16	Bio-Rad Pasteur	Syntetický peptid monomerního typu, prostredek, který ho obsahuje, zpusob imunologické in vitro kvantifikace a diagnostický kit pro použití v biologických testech pro identifikaci infekcí zpusobených viry HIV
CA2290217C (en) *	1998-11-30	2010-01-12	Ortho-Clinical Diagnostics, Inc.	Peptides for the detection of hiv-1 group o
FR2874017B1 (fr) *	2004-08-06	2006-11-24	Bio Rad Pasteur Sa	Peptides vih-1 modifies et leur utilisation en detection d'anticorps anti-vih
EP2864787B1 (en)	2012-06-22	2017-11-01	Bio-Rad Laboratories, Inc.	Human factor xiii as a normalization control for immunoassays
CN112481246B (zh) *	2020-12-16	2022-03-29	熊猫乳品集团股份有限公司	一种生物活性多肽fspankkltpkky及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5204259A (en)	1988-05-06	1993-04-20	Pharmacia Genetic Engineering, Inc.	Methods and systems for producing HIV antigens
ATE174382T1 (de)	1992-10-06	1998-12-15	Dade Behring Marburg Gmbh	Retrovirus aus der hiv-gruppe und dessen verwendung
DE4405810A1 (de) *	1994-02-23	1995-08-24	Behringwerke Ag	Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
GB9410044D0 (en)	1994-05-19	1994-07-06	Int Murex Tech Corp	Assay
DE4430972A1 (de)	1994-07-25	1996-02-01	Boehringer Mannheim Gmbh	Bestimmung von spezifischem Immunglobulin unter Verwendung multipler Antigene
ATE374253T1 (de) *	1994-10-20	2007-10-15	Pasteur Institut	Nukleotiden-sequenzen aus retroviren-antigenen hiv-i gruppe (oder untergruppe) o
DE19505262C2 (de)	1995-02-16	1998-06-18	Behring Diagnostics Gmbh	Retrovirus aus der HIV-Gruppe und dessen Verwendung
FR2731013B1 (fr) *	1995-02-27	1997-05-16	Inst Nat Sante Rech Med	Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
WO1996027012A1 (en)	1995-03-02	1996-09-06	Akzo Nobel N.V.	Specific hiv-1 group o antigens
US5569553A (en)	1995-03-08	1996-10-29	Wilson Greatbatch Ltd.	Battery design for achieving end-of-life indication during electrical discharge
DE19622088A1 (de)	1996-05-31	1997-12-04	Boehringer Mannheim Gmbh	Anti-HIV-Antikörper als Kontrollproben
CZ300927B6 (cs) *	1997-04-09	2009-09-16	Bio-Rad Pasteur	Syntetický peptid monomerního typu, prostredek, který ho obsahuje, zpusob imunologické in vitro kvantifikace a diagnostický kit pro použití v biologických testech pro identifikaci infekcí zpusobených viry HIV
EP1003878A2 (en)	1997-07-18	2000-05-31	Innogenetics N.V.	Hiv-1 group o antigens and uses thereof

1998
- 1998-04-06 CZ CZ0357599A patent/CZ300927B6/cs unknown
- 1998-04-06 AU AU73386/98A patent/AU740231B2/en not_active Expired
- 1998-04-06 EP EP98920571A patent/EP0973802B1/fr not_active Expired - Lifetime
- 1998-04-06 CA CA2286344A patent/CA2286344C/fr not_active Expired - Lifetime
- 1998-04-06 PT PT98920571T patent/PT973802E/pt unknown
- 1998-04-06 CN CNB988052024A patent/CN1215082C/zh not_active Expired - Lifetime
- 1998-04-06 PL PL336115A patent/PL194863B1/pl unknown
- 1998-04-06 DE DE69836265T patent/DE69836265T2/de not_active Expired - Lifetime
- 1998-04-06 WO PCT/FR1998/000691 patent/WO1998045323A1/fr not_active Ceased
- 1998-04-06 ES ES98920571T patent/ES2275305T3/es not_active Expired - Lifetime
- 1998-04-06 AT AT98920571T patent/ATE343590T1/de not_active IP Right Cessation
- 1998-04-06 IL IL13216698A patent/IL132166A0/xx active IP Right Grant
- 1998-04-06 JP JP54245598A patent/JP3560987B2/ja not_active Expired - Lifetime
- 1998-04-06 BR BRPI9809078A patent/BRPI9809078B8/pt not_active IP Right Cessation
- 1998-04-06 RU RU99123443/04A patent/RU2184742C2/ru active
- 1998-04-06 TR TR1999/02757T patent/TR199902757T2/xx unknown
- 1998-04-06 NZ NZ500015A patent/NZ500015A/en not_active IP Right Cessation
- 1998-04-06 US US09/147,362 patent/US7053175B1/en not_active Expired - Lifetime
- 1998-04-06 KR KR10-1999-7009296A patent/KR100451312B1/ko not_active Expired - Lifetime
1999
- 1999-09-30 IL IL132166A patent/IL132166A/en not_active IP Right Cessation
- 1999-10-08 NO NO19994929A patent/NO329149B1/no not_active IP Right Cessation
2006
- 2006-04-13 US US11/402,876 patent/US7838001B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7053175B1 (en)	2006-05-30
PL194863B1 (pl)	2007-07-31
EP0973802B1 (fr)	2006-10-25
CN1256695A (zh)	2000-06-14
JP2001519800A (ja)	2001-10-23
IL132166A (en)	2006-12-10
CN1215082C (zh)	2005-08-17
KR100451312B1 (ko)	2004-10-06
US20060234213A1 (en)	2006-10-19
DE69836265T2 (de)	2007-05-31
RU2184742C2 (ru)	2002-07-10
JP3560987B2 (ja)	2004-09-02
BRPI9809078B8 (pt)	2021-05-25
WO1998045323A1 (fr)	1998-10-15
TR199902757T2 (xx)	2000-02-21
KR20010006216A (ko)	2001-01-26
ATE343590T1 (de)	2006-11-15
US7838001B2 (en)	2010-11-23
IL132166A0 (en)	2001-03-19
CZ300927B6 (cs)	2009-09-16
CA2286344C (fr)	2012-08-07
ES2275305T3 (es)	2007-06-01
BR9809078A (pt)	2000-08-01
PT973802E (pt)	2007-01-31
CA2286344A1 (fr)	1998-10-15
AU7338698A (en)	1998-10-30
DE69836265D1 (de)	2006-12-07
AU740231B2 (en)	2001-11-01
NZ500015A (en)	2001-06-29
NO994929D0 (no)	1999-10-08
CZ357599A3 (cs)	2000-06-14
EP0973802A1 (fr)	2000-01-26
PL336115A1 (en)	2000-06-05
BR9809078B1 (pt)	2012-12-11
NO994929L (no)	1999-12-08

Legal Events

Date	Code	Title	Description
2018-05-07	MK1K	Patent expired

Publication	Publication Date	Title
US4833072A (en)	1989-05-23	Antigentic peptides and process for their preparation
Oldstone et al.	1991	Mapping the anatomy of the immunodominant domain of the human immunodeficiency virus gp41 transmembrane protein: peptide conformation analysis using monoclonal antibodies and proton nuclear magnetic resonance spectroscopy
EP0538283B1 (en)	1997-03-12	Synthetic peptides and mixtures thereof for detecting hiv antibodies
JP2650217B2 (ja)	1997-09-03	Ｈｔｌｖ―１感染の診断、治療及び予防接種のためのペプチド
EP0326490B2 (en)	2004-11-24	Synthetic peptides and mixtures thereof for detecting HIV antibodies
NO329149B1 (no)	2010-08-30	Syntetiske peptider, blandinger, immunoassaymetode og diagnostiseringssett
Pau et al.	2007	Chimeric multiple antigenic peptides for simultaneous detection of specific antibodies to HIV-1 groups M, N, O, and HIV-2
AU636145B2 (en)	1993-04-22	New human parvovirus peptides with disulfide bridge for immunization or diagnosis
CN109836478A (zh)	2019-06-04	非洲猪瘟病毒p11.5蛋白特异性多克隆抗体的制备方法及应用
AU617201B2 (en)	1991-11-21	Novel protein and coding sequence for detection and differentiation of siv and hiv-2 group of viruses
US6214537B1 (en)	2001-04-10	Synthetic peptides and mixtures thereof for detecting HIV antibodies
CA2676762C (en)	2015-12-29	Peptides for the detection of hiv-1 group o
US6218102B1 (en)	2001-04-17	Synthetic peptides and mixtures thereof for detecting HIV antibodies
MXPA99009106A (en)	2000-06-05	Synthetic peptides useful in biological assays for detecting infections caused by group o hiv-1 viruses
HK1028065B (en)	2005-06-10	Peptides for the detection of hiv-1-group o